VKTX Launches $500M Shelf After Full Enrollment Of Phase 3 Obesity Drug Study – Retail Bets On ‘Exceptionally Great Data’

Viking Therapeutics (VKTX) launched a $500 million shelf offering following full enrollment of the Phase 3 study for its obesity drug VK2735.

The proceeds will fund continued development and commercialization of VK2735.

Retail investors are betting on 'exceptionally great data' for VK2735.